Due to the numerous comments received from organizations representing prescribers (including a letter sent May 17 by Ohio Academy of Family Physicians President Tom Houston, MD), the State of Ohio Board of Pharmacy (SOBP), during its meeting on June 6, decided that it was in the best interest of all involved to take a month to assess options as it relates to the non-hazardous prescriber compounding rule (4729-16-04).
As such, the previously issued guidance remains in effect.
As a reminder, for those who have concerns regarding the availability of in-office stock of compounded drugs, the SOBP does license facilities called that are not subject to the limitations in rule 4729-16-07. Please note that rule 4729-16-07 represents a compromise the SOBP worked out with the U.S. Food and Drug Administration.